Edition:
India

Sino Biopharmaceutical Ltd (1177.HK)

1177.HK on Hong Kong Stock

10.34HKD
13 Dec 2019
Change (% chg)

HK$0.02 (+0.19%)
Prev Close
HK$10.32
Open
HK$10.48
Day's High
HK$10.48
Day's Low
HK$10.26
Volume
27,972,701
Avg. Vol
51,452,189
52-wk High
HK$12.24
52-wk Low
HK$4.53

Latest Key Developments (Source: Significant Developments)

Sino Biopharmaceutical Says Argatroban Injection Obtains Approval By NMPA Of PRC
Thursday, 12 Dec 2019 

Dec 12 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::ARGATROBAN INJECTION, DEVELOPED BY UNIT HAS OBTAINED APPROVAL FOR DRUG REGISTRATION GRANTED BY NMPA OF PRC.  Full Article

Sino Biopharmaceutical "Bendamustine Hydrochloride For Injection" Approved For Drug Registration
Wednesday, 11 Dec 2019 

Dec 11 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::"BENDAMUSTINE HYDROCHLORIDE FOR INJECTION" APPROVED FOR DRUG REGISTRATION BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC.  Full Article

Sino Biopharmaceutical Says "Ademetionine 1,4-Butanedisulfonate For Injection" Obtains Regulatory Approval
Tuesday, 10 Dec 2019 

Dec 10 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::"ADEMETIONINE 1,4-BUTANEDISULFONATE FOR INJECTION" OBTAINS APPROVAL FOR DRUG REGISTRATION BY NMPA OF PRC.  Full Article

Sino Biopharmaceutical Says Esomeprazole Sodium For Injection Obtained Drug Registration Approval Granted By NMPA Of PRC
Wednesday, 27 Nov 2019 

Nov 27 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::ESOMEPRAZOLE SODIUM FOR INJECTION HAS OBTAINED APPROVAL FOR DRUG REGISTRATION GRANTED BY NMPA OF PRC.  Full Article

Sino Biopharmaceutical Posts 9-Month Profit Attributable RMB2,255.52 Mln
Tuesday, 26 Nov 2019 

Nov 26 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::DECLARED PAYMENT OF A QUARTERLY DIVIDEND OF HK2 CENTS PER SHARE FOR THREE MONTHS ENDED 30 SEPTEMBER, 2019.NINE MONTHS REVENUE WAS ABOUT RMB19,320.77 MILLION, INCREASE OF 22.8%.9-MONTH PROFIT ATTRIBUTABLE RMB2,255.52 MILLION, ABOUT 2.5% UP.  Full Article

Sino Biopharmaceutical Says Lenalidomide Capsules Gets Approval Of Drug Supplementary Application
Thursday, 21 Nov 2019 

Nov 21 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::UNIT GETS NOD OF DRUG SUPPLEMENTARY APPLICATION BY NMPA OF CHINA FOR ADDITION OF 2 SPECIFICATIONS OF 5MG AND 10MG.  Full Article

Sino Biopharmaceutical Says Fosaprepitant Dimeglumine For Injection Obtains Approval For Drug Registration
Wednesday, 30 Oct 2019 

Oct 30 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::FOSAPREPITANT DIMEGLUMINE FOR INJECTION OBTAINS APPROVAL FOR DRUG REGISTRATION BY NATIONAL DRUG ADMINISTRATION OF PRC.  Full Article

Sino Biopharmaceutical Says Ticagrelor Tablet Obtained Provisional ANDA Approval From U.S. FDA
Monday, 14 Oct 2019 

Oct 14 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::TICAGRELOR TABLET OBTAINED PROVISIONAL APPROVAL OF ABBREVIATED NEW DRUG APPLICATION FROM UNITED STATES FDA.  Full Article

Sino Biopharmaceutical Says Azacitidine Obtained Approval For Drug Registration
Thursday, 10 Oct 2019 

Oct 10 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::AZACITIDINE FOR INJECTION OBTAINED APPROVAL FOR DRUG REGISTRATION FROM NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC.AZACITIDINE IS INDICATED FOR TREATMENT OF ALL SUBTYPES OF MYELODYSPLASTIC SYNDROME AND HAS BEEN GIVEN ORPHAN-DRUG STATUS.  Full Article

Sino Biopharmaceutical Says Anlotinib Hydrochloride Capsules Obtains Approval For Drug Registration
Wednesday, 4 Sep 2019 

Sept 4 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::ANLOTINIB HYDROCHLORIDE CAPSULES OBTAINED APPROVAL FOR DRUG REGISTRATION BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC.  Full Article

China Resources Gas, Sino Biopharmaceutical to join Hang Seng China Enterprises Index

HONG KONG, Nov 8 Hong Kong's stock index compiler said on Friday that China Resources Gas Group Ltd and Sino Biopharmaceutical Ltd have been selected to join the Hang Seng China Enterprises Index, while two companies will be removed.